Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Cougar Biotechnology; Janssen Research & Development; Janssen-Cilag
- 06 Jun 2023 Results of Secondary post-hoc sub-analyses of two randomized clinical trials (NCT00887198, n = 1088 and NCT02257736, n = 982) assessing The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 01 Jun 2023 Results a Secondary Analysis of the COU-AA-302 trial assessing the receipt of prior prostate-directed LT influenced the response to first-line systemic therapy and survival in docetaxel-naive metastatic castrate-resistant prostate cancer (mCRPC) patients published in the European Urology
- 16 May 2023 Results of meta-analysis from PROpel , PREVAIL and COU-AA-302 (AA) treatment arms, Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer, published in the European Urology Open Science